TY - JOUR
T1 - Effects of ibopamine on the increase in plasma norepinephrine levels during exercise in congestive heart failure
AU - van Veldhuisen, Dirk J.
AU - Girbes, Armand R.J.
AU - van den Broek, Stan A.J.
AU - de Graeff, Pieter A.
AU - van Gilst, Wiek H.
AU - Lie, K. I.
PY - 1993/4/15
Y1 - 1993/4/15
N2 - Congestive heart failure (CHF) is accompanied by increased levels of plasma norepinephrine (PNE) at rest. During exercise, PNE levels increase rapidly in patients with CHF,1 causing skeletal vasoconstriction and muscle underperfusion. Because long-term sympathetic activation may be detrimental in patients with CHF,2 inhibition of this sympathetic drive would appear to be beneficial. The oral dopamine agonist ibopamine causes vasodilation and reduces PNE levels at rest in patients with CHF.3 However, the influence of ibopamine on peak oxygen consumption (VO2) and PNE levels during exercise in patients with CHF is unknown, and was investigated in this study.
AB - Congestive heart failure (CHF) is accompanied by increased levels of plasma norepinephrine (PNE) at rest. During exercise, PNE levels increase rapidly in patients with CHF,1 causing skeletal vasoconstriction and muscle underperfusion. Because long-term sympathetic activation may be detrimental in patients with CHF,2 inhibition of this sympathetic drive would appear to be beneficial. The oral dopamine agonist ibopamine causes vasodilation and reduces PNE levels at rest in patients with CHF.3 However, the influence of ibopamine on peak oxygen consumption (VO2) and PNE levels during exercise in patients with CHF is unknown, and was investigated in this study.
UR - http://www.scopus.com/inward/record.url?scp=0027412215&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/0002-9149(93)90920-8
DO - https://doi.org/10.1016/0002-9149(93)90920-8
M3 - Article
C2 - 8465795
SN - 0002-9149
VL - 71
SP - 992
EP - 994
JO - The American Journal of Cardiology
JF - The American Journal of Cardiology
IS - 11
ER -